Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more
116 Huntington Avenue, Boston, MA, 02116, United States
Market Cap
1.243B
52 Wk Range
$7.80 - $20.25
Previous Close
$19.19
Open
$19.34
Volume
648,421
Day Range
$19.21 - $20.02
Enterprise Value
955.3M
Cash
290.2M
Avg Qtr Burn
-29.25M
Insider Ownership
10.59%
Institutional Own.
91.20%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ficerafusp alfa + Pembrolizumab Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 2/3 Data readout | |
Ficerafusp alfa -/+ Pembrolizumab Details 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) | Phase 1b Data readout | |
Ficerafusp alfa Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 1b Update |